Azithromycin role in covid-19 (revenue)

Azithromycin (AZM) is a repurposing antibiotic drug from antimicrobial agents. It defines a broad range like the gramme-positive and gramme-negative spectrums. It has anti-inflammatory properties and an immunoregulatory impact. It prevents respiratory infections, gastrointestinal infections, etc. During the COVID III phase, this drug is most commonly used for isolated patients from all over the world. The suitable dose of this antibiotic is 500–1000 mg consumed daily for approximately 5–7 days. Good tolerability defines its properties in antibacterial parts. It is more widely used indiscriminately in various Indian cities.

According to our country’s latest reports, azithromycin usage is increasing day by day following the COVID pandemic. These anti-inflammatory tablets are safe, cheap, and easily available. During the COVID pandemic of 2020–2021, azithromycin 121 trials will be given to the clinical laboratory for testing. Basically, hydroxychloroquine supports azithromycin as prescribed. However, during the COVID-19 pandemic, it gained attention as a potential treatment for the virus.

Some early studies suggested that azithromycin, when used in combination with hydroxychloroquine, could be effective in treating COVID-19. However, subsequent studies found no benefit in using azithromycin alone or in combination with other drugs for COVID-19 treatment.

Despite the lack of scientific evidence, some doctors continued to prescribe azithromycin for COVID-19 patients. This led to concerns about the overuse of antibiotics, which can contribute to antibiotic resistance.

The use of azithromycin in COVID-19 treatment also had financial implications. The drug’s manufacturer, Pfizer, reported a significant increase in revenue in the second quarter of 2020, which was attributed to increased demand for azithromycin during the pandemic.

However, it’s important to note that azithromycin is not a recommended treatment for COVID-19, and that its use should be limited to bacterial infections. The World Health Organisation and the Centres for Disease Control and Prevention do not recommend the use of azithromycin for COVID-19 treatment outside of clinical trials.

In conclusion, while azithromycin may have a role in treating bacterial infections, its effectiveness in treating COVID-19 is uncertain, and its use should be limited to cases where it’s medically necessary. The financial gains from increased demand for azithromycin during the pandemic should not outweigh the importance of evidence-based medicine and responsible use of antibiotics.

Leave a Reply